Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDI-1228_mesylate gel in mild-to-moderate atopic dermatitis (Phase II)
CTR20233049Phase 2Completed
- Sponsor
- Henan Maino Pharmaceutical Technology
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MDI-1228_mesylate gel with Placebo gel (2 arms). Primary endpoints: Safety: adverse events during treatment, Safety: local skin adverse events and 3 more. Started Sep 2023; status: completed.
02
Drugs
MDI-1228
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233049.